Aspirin-intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin d2 (PGD2) metabolites

Allergology International

Volumn 61, Issue 3, 2012, Pages 393-403

  Higashi, Noritaka ^a   Taniguchi, Masami ^a   Mita, Haruhisa ^a   Yamaguchi, Hiromichi ^a   Ono, Emiko ^a   Akiyama, Kazuo ^a  

^a SAGAMIHARA NATIONAL HOSPITAL   (Japan)

Author keywords

Aspirin; Asthma; Biomarker; Cysteinyl leukotriene; Mast cell; Urine

Indexed keywords

1,15 DIOXO 9' HYDROXY 2,3,4,5 TETRANORPROSTAN 1,20 DIOIC ACID; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; ISOPROSTANE; LEUKOTRIENE E4; LIPOXIN A; PROSTAGLANDIN D2; UNCLASSIFIED DRUG;

ASPIRIN EXACERBATED RESPIRATORY DISEASE; BIOSYNTHESIS; BRONCHOSPASM; CELL ACTIVATION; CHEMICAL STRUCTURE; CLINICAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY CONCENTRATING CAPACITY; MAST CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; URINALYSIS;

ASTHMA, ASPIRIN-INDUCED; BIOLOGICAL MARKERS; HUMANS; LEUKOTRIENE E4; PROSTAGLANDIN D2; PROSTAGLANDINS;

EID: 84867835703     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.11-RA-0403     Document Type: Review

References (96)

1. Samter M, Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968;68:975-983.
2. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006;118:773-786; quiz 87-88.
3. Gyllfors P, Bochenek G, Overholt J et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 2003;111:1116-1121.
4. Dahlen B, Szczeklik A, Murray JJ. Celecoxib in patients with asthma and aspirin intolerance. The Celecoxib in Aspirin-Intolerant Asthma Study Group. N Engl J Med 2001;344:142.
5. Group TES. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003;22:470-477.
6. Moore WC, Bleecker ER, Curran-Everett D et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:405-413.
7. Dolan CM, Fraher KE, Bleecker ER et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004;92:32-39.
8. Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest 2007;132:1882-1889.
9. Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005;116:970-975.
10. Williams WR, Pawlowicz A, Davies BH. In vitro tests for the diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol 1990;86:445-451.
11. Okuda Y, Hattori H, Takashima T et al. Basophil histamine release by platelet-activating factor in aspirinsensitive subjects with asthma. J Allergy Clin Immunol 1990;86:548-553.
12. Czech W, Schöpf E, Kapp A. Release of sulfidoleukotrienes in vitro: its relevance in the diagnosis of pseudoallergy to acetylsalicylic acid. Inflamm Res 1995;44: 291-295.
13. Mewes T, Riechelmann H, Klimek L. Increased in vitro cysteinyl leukotriene release from blood leukocytes in patients with asthma, nasal polyps, and aspirin intolerance. Allergy 1996;51:506-510.
14. Pierzchalska M, Mastalerz L, Sanak M, Zazula M, Szczeklik A. A moderate and unspecific release of cysteinyl leukotrienes by aspirin from peripheral blood leucocytes precludes its value for aspirin sensitivity testing in asthma. Clin Exp Allergy 2000;30:1785-1791.
15. Bavbek S, Dursun AB, Birben E, Kalayci O, Misirligil Z. Cellular allergen stimulation test with acetylsalicylic acidlysine is not a useful test to discriminate between asthmatic patients with and without acetylsalicylic acid sensitivity. Int Arch Allergy Immunol 2009;149:58-64.
16. Dworski R, Sheller JR. Urinary mediators and asthma. Clin Exp Allergy 1998;28:1309-1312.
17. Kumlin M. Measurements of leukotrienes in the urine: strategies and applications. Allergy 1997;52:124-135.
18. Denzlinger C, Guhlmann A, Scheuber PH, Wilker D, Hammer DK, Keppler D. Metabolism and analysis of cysteinyl leukotrienes in the monkey. J Biol Chem 1986;261: 15601-1566.
19. Maltby NH, Taylor GW, Ritter JM, Moore K, Fuller RW, Dollery CT. Leukotriene C4 elimination and metabolism in man. J Allergy Clin Immunol 1990;85:3-9.
20. Orning L, Kaijser L, Hammarstrom S. In vivo metabolism of leukotriene C4 in man: urinary excretion of leukotriene E4. Biochem Biophys Res Commun 1985;130:214-220.
21. Mita H, Oosaki R, Mizushima Y, Kobayashi M, Akiyama K. Efficient method for the quantitation of urinary leukotriene E4: extraction using an Empore C18 disk cartridge. J Chromatogr B Biomed Sci Appl 1997;692:461-466.
22. Armstrong M, Liu AH, Harbeck R, Reisdorph R, Rabinovitch N, Reisdorph N. Leukotriene-E4 in human urine: Comparison of on-line purification and liquid chromatography- tandem mass spectrometry to affinity purification followed by enzyme immunoassay. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:3169-3174.
23. Christie PE, Tagari P, Ford-Hutchinson AW et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991;143:1025-1029.
24. Gaber F, Daham K, Higashi A et al. Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. Thorax 2008;63:1076-1082.
25. Higashi N, Mita H, Ono E et al. Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J Allergy Clin Immunol 2010; 125:1084-1091.e6.
26. Higashi N, Taniguchi M, Mita H et al. Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 2004;113:277-283.
27. Higashi N, Taniguchi M, Mita H, Osame M, Akiyama K. A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. Clin Exp Allergy 2002;32:1484-1490.
28. Mita H, Endoh S, Kudoh M et al. Possible involvement of mast-cell activation in aspirin provocation of aspirininduced asthma. Allergy 2001;56:1061-1067.
29. Kumlin M, Dahlen B, Bjorck T, Zetterstrom O, Granstrom E, Dahlen SE. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dis 1992;146:96-103.
30. Kawagishi Y, Mita H, Taniguchi M et al. Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 2002; 109:936-942.
31. Oosaki R, Mizushima Y, Mita H, Shida T, Akiyama K, Kobayashi M. Urinary leukotriene E4 and 11-dehydrothromboxane B2 in patients with aspirin-sensitive asthma. Allergy 1997;52:470-473.
32. Sampson AP, Cowburn AS, Sladek K et al. Profound overexpression of leukotriene C4 synthase in bronchial biopsies from aspirin-intolerant asthmatic patients. Int Arch Allergy Immunol 1997;113:355-357.
33. Cowburn AS, Sladek K, Soja J et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101:834-846.
34. Cai Y, Bjermer L, Halstensen TS. Bronchial mast cells are the dominating LTC4S-expressing cells in aspirin-tolerant asthma. Am J Respir Cell Mol Biol 2003;29:683-693.
35. Taniguchi M, Higashi N, Ono E, Mita H, Akiyama K. Hyperleukotrieneuria in patients with allergic and inflammatory disease. Allergol Int 2008;57:313-320.
36. Bousquet J, Reid J, van Weel C et al. Allergic rhinitis management pocket reference 2008. Allergy 2008;63:990-996.
37. Back M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther 2009;23:41-48.
38. Carry M, Korley V, Willerson JT, Weigelt L, Ford-Hutchinson AW, Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 1992;85: 230-236.
39. Higashi N, Mita H, Taniguchi M et al. Urinary eicosanoid and tyrosine derivative concentrations in patients with vasculitides. J Allergy Clin Immunol 2004;114:1353-1358.
40. Fauler J, Frolich JC. Cigarette smoking stimulates cysteinyl leukotriene production in man. Eur J Clin Invest 1997; 27:43-47.
41. Stanke-Labesque F, Bäck M, Lefebvre B et al. Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia. J Allergy Clin Immunol 2009;124:364-370, 70.e1-2.
42. Wu X, Cai H, Xiang YB et al. Intra-person variation of urinary biomarkers of oxidative stress and inflammation. Cancer Epidemiol Biomarkers Prev 2010;19:947-952.
43. Frolich JC, Wilson TW, Sweetman BJ et al. Urinary prostaglandins. Identification and origin. J Clin Invest 1975;55:763-770.
44. Kowalski ML, Pawliczak R, Wozniak J et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000;161:391-398.
45. Perez-Novo CA, Watelet JB, Claeys C, Van Cauwenberge P, Bachert C. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. J Allergy Clin Immunol 2005;115:1189-1196.
46. Picado C, Fernandez-Morata JC, Juan M et al. Cyclooxygenase- 2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1999;160:291-296.
47. Pujols L, Mullol J, Alobid I, Roca-Ferrer J, Xaubet A, Picado C. Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma. J Allergy Clin Immunol 2004;114:814-819.
48. Sestini P, Armetti L, Gambaro G et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996;153:572-575.
49. Yamaguchi H, Higashi N, Mita H et al. Urinary concentrations of 15-epimer of lipoxin A(4) are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma. Clin Exp Allergy 2011;41:1711-1718.
50. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat 2002; 68-69:433-455.
51. Levy BD, De Sanctis GT, Devchand PR et al. Multipronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med 2002;8:1018-1023.
52. Clish CB, Levy BD, Chiang N, Tai HH, Serhan CN. Oxidoreductases in lipoxin A4 metabolic inactivation: a novel role for 15-onoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in inflammation. J Biol Chem 2000;275:25372-25380.
53. Lewis RA, Soter NA, Diamond PT, Austen KF, Oates JA, Roberts LJ 2nd. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 1982;129:1627-1631.
54. Kanaoka Y, Urade Y. Hematopoietic prostaglandin D synthase. Prostaglandins Leukot Essent Fatty Acids 2003;69: 163-167.
55. Dahlen SE, Kumlin M. Monitoring mast cell activation by prostaglandin D2 in vivo. Thorax 2004;59:453-455.
56. O'Sullivan S. On the role of PGD2 metabolites as markers of mast cell activation in asthma. Acta Physiol Scand Suppl 1999;644:1-74.
57. Treudler R, Kozovska Y, Simon JC. Severe immediate type hypersensitivity reactions in 105 German adults: when to diagnose anaphylaxis. J Investig Allergol Clin Immunol 2008;18:52-58.
58. Bochenek G, Nizankowska E, Gielicz A, Swierczynska M, Szczeklik A. Plasma 9alpha,11beta-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma. Thorax 2004;59:459-464.
59. Ono E, Taniguchi M, Mita H et al. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis. Clin Exp Allergy 2009;39:72-80.
60. O'Sullivan S, Mueller MJ, Dahlen SE, Kumlin M. Analyses of prostaglandin D2 metabolites in urine: comparison between enzyme immunoassay and negative ion chemical ionisation gas chromatography-mass spectrometry. Prostaglandins Other Lipid Mediat 1999;57:149-165.
61. Song WL, Wang M, Ricciotti E et al. Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. J Biol Chem 2008; 283:1179-1188.
62. Higashi N, Mita H, Yamaguchi H, Fukutomi Y, Akiyama K, Taniguchi M. Urinary tetranor-PGDM concentrations in aspirin-intolerant asthma and anaphylaxis. J Allergy Clin Immunol 2012;129:557-559.
63. Morrow JD, Guzzo C, Lazarus G, Oates JA, Roberts LJ 2nd. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. J Invest Dermatol 1995;104:937-940.
64. Bochenek G, Nagraba K, Nizankowska E, Szczeklik A. A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 2003;111:743-749.
65. Nasser SM, Pfister R, Christie PE et al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med 1996;153: 90-96.
66. Sousa AR, Lams BE, Pfister R, Christie PE, Schmitz M, Lee TH. Expression of interleukin-5 and granulocytemacrophage colony-stimulating factor in aspirin-sensitive and non-aspirin-sensitive asthmatic airways. Am J Respir Crit Care Med 1997;156:1384-1389.
67. Mastalerz L, Sanak M, Gawlewicz-Mroczka A, Gielicz A, Cmiel A, Szczeklik A. Prostaglandin E2 systemic production in patients with asthma with and without aspirin hypersensitivity. Thorax 2008;63:27-34.
68. Daham K, Song WL, Lawson JA et al. Effects of celecoxib on major prostaglandins in asthma. Clin Exp Allergy 2011; 41:36-45.
69. Taniguchi M. [Measurement of airway hyperresponsiveness and aspirin sensitivity]. Arerugi 2009;58:87-96(in Japanese).
70. Mita H, Higashi N, Taniguchi M, Higashi A, Akiyama K. Increase in urinary leukotriene B glucuronide concentration in patients with aspirin-intolerant asthma after intravenous aspirin challenge. Clin Exp Allergy 2004;34:1262-1269.
71. Mita H, Higashi N, Taniguchi M, Higashi A, Kawagishi Y, Akiyama K. Urinary 3-bromotyrosine and 3-chlorotyrosine concentrations in asthmatic patients: lack of increase in 3-bromotyrosine concentration in urine and plasma proteins in aspirin-induced asthma after intravenous aspirin challenge. Clin Exp Allergy 2004;34:931-938.
72. Stevenson DD, Simon RA, Mathison DA, Christiansen SC. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics. Ann Allergy Asthma Immunol 2000;85:477-482.
73. Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 1988;137: 847-854.
74. Kroegel C, Matthys H. Platelet-activating factor-induced human eosinophil activation. Generation and release of cyclo-oxygenase metabolites in human blood eosinophils from asthmatics. Immunology 1993;78:279-285.
75. Parsons WG 3rd, Roberts LJ 2nd. Transformation of prostaglandin D2 to isomeric prostaglandin F2 compounds by human eosinophils. A potential mast celleosinophil interaction. J Immunol 1988;141:2413-2419.
76. Weller PF, Lee CW, Foster DW, Corey EJ, Austen KF, Lewis RA. Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. Proc Natl Acad Sci U S A 1983;80:7626-7630.
77. Luna-Gomes T, Magalhaes KG, Mesquita-Santos FP et al. Eosinophils as a novel cell source of prostaglandin d2: autocrine role in allergic inflammation. J Immunol 2011; 187:6518-6526.
78. Sladek K, Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Respir J 1993;6:391-399.
79. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 125:S73-S80.
80. Awad JA, Morrow JD, Takahashi K, Roberts LJ 2nd. Identification of non-cyclooxygenase-derived prostanoid (F2- isoprostane) metabolites in human urine and plasma. J Biol Chem 1993;268:4161-4169.
81. Gao L, Zackert WE, Hasford JJ et al. Formation of prostaglandins E2 and D2 via the isoprostane pathway: a mechanism for the generation of bioactive prostaglandins independent of cyclooxygenase. J Biol Chem 2003;278: 28479-28489.
82. Yin H, Gao L, Tai HH, Murphey LJ, Porter NA, Morrow JD. Urinary prostaglandin F2alpha is generated from the isoprostane pathway and not the cyclooxygenase in humans. J Biol Chem2007;282:329-336.
83. Xu L, Han C, Lim K, Wu T. Activation of cytosolic phospholipase A2alpha through nitric oxide-induced Snitrosylation. Involvement of inducible nitric-oxide synthase and cyclooxygenase-2. J Biol Chem 2008;283:3077-3087.
84. Kim SF, Huri DA, Snyder SH. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase- 2. Science 2005;310:1966-19670.
85. He P, Laidlaw T, Maekawa A, Kanaoka Y, Xu K, Lam BK. Oxidative stress suppresses cysteinyl leukotriene generation by mouse bone marrow-derived mast cells. J Biol Chem 2011;286:8277-8286.
86. Ono E, Taniguchi M, Higashi N et al. Increase in salivary cysteinyl-leukotriene concentration in patients with aspirin-intolerant asthma. Allergol Int 2011;60:37-43.
87. Ono E, Mita H, Taniguchi M et al. Comparison of cysteinyl leukotriene concentrations between exhaled breath condensate and bronchoalveolar lavage fluid. Clin Exp Al lergy 2008;38:1866-1874.
88. Ono E, Mita H, Taniguchi M et al. Increase in inflammatory mediator concentrations in exhaled breath condensate after allergen inhalation. J Allergy Clin Immunol 2008; 122:768-773.e1.
89. Ono E, Mita H, Taniguchi M et al. Concentration of 14,15- leukotriene C4 (eoxin C4) in bronchoalveolar lavage fluid. Clin Exp Allergy 2009;39:1348-1352.
90. Christie PE, Schmitz-Schumann M, Spur BW, Lee TH. Airway responsiveness to leukotriene C4 (LTC4), leukotriene E4 (LTE4) and histamine in aspirin-sensitive asthmatic subjects. Eur Respir J 1993;6:1468-1473.
91. Feng C, Mery AG, Beller EM, Favot C, Boyce JA. Adenine nucleotides inhibit cytokine generation by human mast cells through a Gs-coupled receptor. J Immunol 2004;173:7539-7547.
92. Nonaka Y, Hiramoto T, Fujita N. Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun 2005;337:281-288.
93. Maekawa A, Kanaoka Y, Xing W, Austen KF. Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A 2008;105:16695-1700.
94. Paruchuri S, Tashimo H, Feng C et al. Leukotriene E4- induced pulmonary inflammation is mediated by the P2Y12 receptor. J ExpMed 2009;206:2543-2555.
95. O'Sullivan S, Dahlen B, Dahlen SE, Kumlin M. Increased urinary excretion of the prostaglandin D2 metabolite 9 alpha, 11 beta-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol 1996;98:421-432.
96. Paruchuri S, Jiang Y, Feng C, Francis SA, Plutzky J, Boyce JA. Leukotriene E4 activates peroxisome proliferator- activated receptor gamma and induces prostaglandin D2 generation by human mast cells. J Biol Chem2008; 283:16477-1687.